Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 9 | 2023 | 386 | 4.090 |
Why?
|
| Liver Neoplasms | 9 | 2023 | 736 | 3.530 |
Why?
|
| Pancreatic Neoplasms | 4 | 2020 | 645 | 1.470 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2020 | 108 | 1.390 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2020 | 70 | 1.360 |
Why?
|
| Endothelial Cells | 4 | 2013 | 429 | 1.090 |
Why?
|
| Circulating Tumor DNA | 2 | 2022 | 37 | 1.030 |
Why?
|
| RNA-Binding Proteins | 2 | 2021 | 249 | 0.810 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 266 | 0.750 |
Why?
|
| HMGA2 Protein | 1 | 2020 | 14 | 0.750 |
Why?
|
| Epithelial Cells | 3 | 2018 | 669 | 0.700 |
Why?
|
| Neoplasm Metastasis | 4 | 2021 | 1056 | 0.690 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2019 | 33 | 0.690 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2017 | 48 | 0.600 |
Why?
|
| Cisplatin | 1 | 2019 | 612 | 0.580 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 158 | 0.550 |
Why?
|
| Precancerous Conditions | 1 | 2017 | 196 | 0.550 |
Why?
|
| MicroRNAs | 1 | 2020 | 534 | 0.520 |
Why?
|
| Neoplasms | 3 | 2013 | 2898 | 0.430 |
Why?
|
| Stromal Cells | 2 | 2019 | 143 | 0.400 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2023 | 106 | 0.400 |
Why?
|
| Humans | 25 | 2023 | 86656 | 0.380 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 353 | 0.350 |
Why?
|
| Tumor Microenvironment | 3 | 2019 | 418 | 0.300 |
Why?
|
| Inflammation | 1 | 2013 | 923 | 0.300 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2023 | 166 | 0.230 |
Why?
|
| Colorectal Neoplasms | 2 | 2021 | 938 | 0.230 |
Why?
|
| Mice, Inbred NOD | 2 | 2020 | 187 | 0.220 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 2426 | 0.220 |
Why?
|
| Mice, SCID | 2 | 2020 | 252 | 0.220 |
Why?
|
| Liver Cirrhosis | 2 | 2023 | 300 | 0.210 |
Why?
|
| Quinolines | 1 | 2023 | 95 | 0.210 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2021 | 36 | 0.200 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2021 | 7 | 0.200 |
Why?
|
| Ribosomes | 1 | 2021 | 111 | 0.200 |
Why?
|
| Biomarkers, Tumor | 3 | 2023 | 1464 | 0.190 |
Why?
|
| Peritoneal Neoplasms | 1 | 2022 | 177 | 0.190 |
Why?
|
| Carcinoma | 1 | 2023 | 436 | 0.180 |
Why?
|
| Rectal Neoplasms | 1 | 2021 | 116 | 0.180 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 162 | 0.180 |
Why?
|
| Female | 13 | 2023 | 44547 | 0.180 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 318 | 0.180 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 212 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 456 | 0.170 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2019 | 36 | 0.170 |
Why?
|
| Japan | 1 | 2019 | 307 | 0.170 |
Why?
|
| Liquid Biopsy | 1 | 2018 | 33 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 1197 | 0.160 |
Why?
|
| Middle Aged | 8 | 2022 | 25036 | 0.160 |
Why?
|
| Quality of Life | 2 | 2023 | 1585 | 0.160 |
Why?
|
| Adult | 8 | 2022 | 25657 | 0.160 |
Why?
|
| Deoxycytidine | 1 | 2019 | 237 | 0.160 |
Why?
|
| Neuroblastoma | 1 | 2021 | 375 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 861 | 0.160 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 159 | 0.150 |
Why?
|
| Aged | 6 | 2021 | 18421 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2019 | 199 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 744 | 0.150 |
Why?
|
| Animals | 6 | 2020 | 26590 | 0.150 |
Why?
|
| Cell Movement | 1 | 2020 | 758 | 0.140 |
Why?
|
| Liver Diseases | 1 | 2018 | 239 | 0.140 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 6513 | 0.140 |
Why?
|
| Male | 9 | 2023 | 40984 | 0.130 |
Why?
|
| Mice, Knockout | 1 | 2020 | 1924 | 0.130 |
Why?
|
| Biomarkers | 1 | 2021 | 1719 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 589 | 0.130 |
Why?
|
| Prognosis | 2 | 2021 | 3680 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1807 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 1313 | 0.110 |
Why?
|
| Angioplasty, Balloon | 1 | 2013 | 95 | 0.110 |
Why?
|
| Sirolimus | 1 | 2013 | 170 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1579 | 0.100 |
Why?
|
| Uremia | 1 | 2011 | 15 | 0.100 |
Why?
|
| Mutation | 1 | 2022 | 3968 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 2360 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 551 | 0.100 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2011 | 21 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2587 | 0.100 |
Why?
|
| Mice | 3 | 2019 | 11356 | 0.100 |
Why?
|
| Cells, Cultured | 2 | 2013 | 2819 | 0.090 |
Why?
|
| Culture Media, Conditioned | 1 | 2011 | 104 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 3642 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 391 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2011 | 256 | 0.090 |
Why?
|
| Transcriptome | 1 | 2013 | 580 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2020 | 7998 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2011 | 376 | 0.080 |
Why?
|
| Phenotype | 1 | 2013 | 2380 | 0.070 |
Why?
|
| Apoptosis | 1 | 2013 | 1683 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 3095 | 0.070 |
Why?
|
| Disease Progression | 1 | 2011 | 1532 | 0.070 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2023 | 12 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2023 | 41 | 0.060 |
Why?
|
| Phenylurea Compounds | 1 | 2023 | 114 | 0.050 |
Why?
|
| Hematologic Tests | 1 | 2021 | 14 | 0.050 |
Why?
|
| Standard of Care | 1 | 2022 | 79 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2023 | 223 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 86 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2022 | 138 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 180 | 0.050 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 65 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 329 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2023 | 485 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 70 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 78 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 98 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2019 | 164 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 2262 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2019 | 222 | 0.040 |
Why?
|
| Proteins | 1 | 2023 | 777 | 0.040 |
Why?
|
| Transfection | 1 | 2019 | 896 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2022 | 1991 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2019 | 615 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2023 | 2768 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 1578 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2018 | 973 | 0.030 |
Why?
|
| Femoral Artery | 1 | 2013 | 81 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2013 | 135 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2013 | 290 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2504 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 4215 | 0.030 |
Why?
|
| Swine | 1 | 2013 | 555 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 178 | 0.030 |
Why?
|
| Serum | 1 | 2011 | 25 | 0.030 |
Why?
|
| Culture Media | 1 | 2011 | 147 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2013 | 460 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2022 | 3361 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2023 | 8495 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 969 | 0.020 |
Why?
|